MIDD In Early Oncology Clinical Development: Dose Optimization

Dose optimization has become an increasingly challenging, but necessary task as developers explore more next-generation oncology therapies and novel combinations. Find out how model-informed drug development (MIDD) can play an integral role in keeping vital oncology trials on track to deliver life-saving therapies to patients in need.


Get an inside look at:


  • Dose optimization and its challenges in novel modalities
  • Addressing dose optimization early in oncologic therapy development
  • How to anticipate and address worldwide regulatory hurdles
  • Using MIDD to quantitatively evaluate efficacy and safety
  • The future of early oncology development


Sign up to our content service and access now

  • Please select...

Opt In?